Literature DB >> 15999287

[Dapsone-induced agranulocytosis. The role of xenobiotic-metabolizing enzymes demonstrated by a case report].

T K Hoffmann1, S von Schmiedeberg, M Wulferink, R Thier, H Bier, T Ruzicka, P Lehmann.   

Abstract

A 34-year-old female patient with a three year history of generalized granuloma annulare was treated systemically with dapsone (DADPS). Six weeks after the onset of treatment, the patient developed an extensive tonsillitis of the base of the tongue with fever and malaise. Routine laboratory work showed a leukocytopenia with agranulocytosis. Further investigation revealed a marked decrease of the enzyme activity of N-acetyltransferase 2, which plays an important role in dapsone metabolism. Treatment included the cessation of dapsone, antibiotic coverage, and G-CSF leading to the rapid improvement of symptoms and normalization of leukocyte counts. Dapsone-induced angina agranulocytotica is a rare event and is interpreted as an idiosyncratic reaction. Depending on genetic polymorphisms of various enzymes, dapsone can be metabolized to immunologically or toxicologically relevant intermediates. Because of the risk of severe hematologic reactions, dapsone should only be employed for solid indications and with appropriate monitoring.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15999287     DOI: 10.1007/s00105-004-0877-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  31 in total

1.  Dapsone hypersensitivity syndrome.

Authors:  R Prussick; N H Shear
Journal:  J Am Acad Dermatol       Date:  1996-08       Impact factor: 11.527

2.  Sulfone treatment of granuloma annulare.

Authors:  A Steiner; H Pehamberger; K Wolff
Journal:  J Am Acad Dermatol       Date:  1985-12       Impact factor: 11.527

3.  Generalized granuloma annulare: clinical and laboratory findings in 100 patients.

Authors:  K Dabski; R K Winkelmann
Journal:  J Am Acad Dermatol       Date:  1989-01       Impact factor: 11.527

Review 4.  Drug-induced agranulocytosis.

Authors:  H Heimpel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

5.  Dapsone-induced agranulocytosis: spontaneous reporting data.

Authors:  E M Cockburn; S M Wood; P C Waller; S S Bleehen
Journal:  Br J Dermatol       Date:  1993-06       Impact factor: 9.302

6.  Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.

Authors:  I Cascorbi; N Drakoulis; J Brockmöller; A Maurer; K Sperling; I Roots
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

Review 7.  The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions.

Authors:  J P Uetrecht
Journal:  Drug Metab Rev       Date:  1992       Impact factor: 4.518

8.  Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo.

Authors:  A K Mitra; K E Thummel; T F Kalhorn; E D Kharasch; J D Unadkat; J T Slattery
Journal:  Clin Pharmacol Ther       Date:  1995-11       Impact factor: 6.875

9.  Agranulocytosis caused by dapsone therapy for granuloma annulare.

Authors:  M N Potter; P Yates; R Slade; C T Kennedy
Journal:  J Am Acad Dermatol       Date:  1989-01       Impact factor: 11.527

10.  N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system.

Authors:  J P Uetrecht; N H Shear; N Zahid
Journal:  Drug Metab Dispos       Date:  1993 Sep-Oct       Impact factor: 3.922

View more
  3 in total

1.  [Adverse drugs reactions: diagnosis and assessment].

Authors:  P A Thürmann
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

2.  Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity.

Authors:  Mahmoud Abouraya; James C Sacco; Kristie Hayes; Sajeve Thomas; Craig S Kitchens; Lauren A Trepanier
Journal:  J Clin Pharmacol       Date:  2012-02       Impact factor: 3.126

Review 3.  Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review.

Authors:  Chang-Yu Hsieh; Tsen-Fang Tsai
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.